









Markets
/
Stocks
/
nasdaq-mrvi
/

Maravai LifeSciences Holdings Inc

MRVI

3.140USD

+0.050+1.62%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

454.41MMarket Cap

LossP/E TTM



Maravai LifeSciences Holdings Inc

3.140

+0.050+1.62%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Maravai LifeSciences Holdings Inc

Currency: USD Updated: 2026-02-06

Key Insights

Maravai LifeSciences Holdings Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 96 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.93.In the medium term, the stock price is expected to remain stable.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Maravai LifeSciences Holdings Inc's Score

Industry at a Glance

Industry Ranking

96 / 392

Overall Ranking

224 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Maravai LifeSciences Holdings Inc Highlights

StrengthsRisks

Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.

Fairly Valued

The company’s latest PE is -3.74, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 130.36M shares, decreasing 22.89% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 14.30K shares of this stock.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

3.929

Target Price

+20.14%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Maravai LifeSciences Holdings Inc is 7.24, ranking 137 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 41.63M, representing a year-over-year decrease of 36.15%, while its net profit experienced a year-over-year decrease of 74.20%.

Score

Industry at a Glance

Previous score

7.24

Change



Financials

6.87

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.94

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.17

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.19

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Maravai LifeSciences Holdings Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Maravai LifeSciences Holdings Inc is 7.48, ranking 116 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.74, which is -1513.33% below the recent high of 52.87 and -205.26% above the recent low of -11.42.

Score

Industry at a Glance

Previous score

7.48

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 96/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Maravai LifeSciences Holdings Inc is 7.27, ranking 303 out of 392 in the Biotechnology & Medical Research industry. The average price target is 4.00, with a high of 5.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

7.27

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

3.929

Target Price

+20.14%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Maravai LifeSciences Holdings Inc

MRVI

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Maravai LifeSciences Holdings Inc is 5.69, ranking 300 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.81 and the support level at 2.77, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.61

Change

0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.150

Sell

RSI(14)

35.243

Neutral

STOCH(KDJ)(9,3,3)

8.162

Oversold

ATR(14)

0.189

Low Volatility

CCI(14)

-113.548

Sell

Williams %R

92.391

Oversold

TRIX(12,20)

-0.386

Sell

StochRSI(14)

33.190

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

3.226

Sell

MA10

3.384

Sell

MA20

3.620

Sell

MA50

3.583

Sell

MA100

3.373

Sell

MA200

2.859

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Maravai LifeSciences Holdings Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 89.89%, representing a quarter-over-quarter increase of 1.09%. The largest institutional shareholder is The Vanguard, holding a total of 7.17M shares, representing 4.94% of shares outstanding, with 38.85% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

GTCR Golder Rauner, LLC

20.15M

12 West Capital Management, L.P.

12.52M

Hudson View Capital LLC

8.94M

+30.22%

Braidwell LP

8.35M

BlackRock Institutional Trust Company, N.A.

7.69M

-8.54%

The Vanguard Group, Inc.

Star Investors

7.13M

-24.04%

T. Rowe Price Investment Management, Inc.

6.16M

+132.94%

Mackenzie Investments

6.07M

Renaissance Technologies LLC

Star Investors

4.32M

+3.15%

Mirabella Financial Services LLP

3.75M

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Maravai LifeSciences Holdings Inc is 4.60, ranking 79 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.40. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.